Skip to main content
. 2008 Dec 12;64(2):361–369. doi: 10.1007/s00280-008-0882-8

Fig. 1.

Fig. 1

Overall survival curve (solid line) and progression-free survival curve (dot line) of patients with HER2 overexpressing metastatic breast cancers with capecitabine and trastuzumab combination chemotherapy resistant to both anthracyclines and taxanes